(no title)
brianleb | 1 year ago
This is the only publication I found in a quick search:
https://pubmed.ncbi.nlm.nih.gov/37976118/
>> Abstract
Objectives: Nerve growth factor β (β-NGF) is a protein which is important to the development of neurons particularly those involved in the transmission of pain and is central to the experience of pain in osteoarthritis (OA). Direct NGF antagonism has been shown to reduce OA pain but is associated with rapidly progressive OA. The aim of the study is to investigate the ability of soluble neurotrophin receptors in the NGF pathway to modulate pain in OA.
Methods: Synovial fluid (SF) was obtained from the knee joints of 43 subjects who underwent total knee arthroplasty. Visual analogue scale (VAS) pain scores were obtained prior to surgery. Customised-automated-ELISAs and commercial-ELISAs and LEGENDplex™ were used to measure soluble low-affinity nerve growth factor (LNGFR), soluble tropomyosin receptor kinase (TrkA), proNGF, β-NGF, other neurotrophins (NT) and cytokines including inflammatory marker TNF-α.
Results: The VAS score positively correlated with β-NGF (r=0.34) and there was positive association trend with neurotrophin-3 (NT-3), BDNF and negative association trend with ProNGF. sLNGFR positively correlated with VAS (r=0.33). The β-NGF/soluble TrkA ratio showed a strong positive correlation with VAS (r=0.80). In contrast, there was no correlation between pain and the β-NGF/sLNGFR ratio (r=-0.08). TNF-α positively correlated with β-NGF (r=0.83), NT-3 (r=0.66), and brain-derived neurotrophic factor (BDNF) (r=0.50) and negatively with ProNGF (r= -0.74) and positively correlated with both soluble TrkA (r=0.62), sLNGFR (r=0.26).
Conclusions: This study suggests that endogenous or cleaved sLNGFR, but not soluble TrkA may participate in OA pain modulation thus supporting further research into soluble LNGFR as a therapeutic target in OA.
ramraj07|1 year ago
Sounds significant. Phase II is typically not enough to tell if a drug is good because most drugs aren’t that effective compared to current standard of care- you need the large numbers of phase iii to see the real difference. But looks like this drug shows a marked improvement in phase ii itself so it’s actually quite impressive. Last time I read such a story was for imatinib. Expecting good things from this.
papercrane|1 year ago
They haven't posted the results yet. They have posted a press release saying the results were positive and that they will post the results in a peer reviewed journal. https://levicept.com/wp-content/uploads/2024/08/Levicept-Cli...
vjk800|1 year ago
I was thinking it would be something that helps the worn ligament grow back. That I would consider a real cure.
datameta|1 year ago
pdfernhout|1 year ago
The big problem in our current society is that there is no substantial money to be made by big companies in promoting these sorts of cures.
LoganDark|1 year ago
> I was thinking it would be something that helps the worn ligament grow back. That I would consider a real cure.
As far as I can tell, that is what it does:
> The drug is based on a molecule he discovered while working at Pfizer, and can be delivered via a once-a-month EpiPen-style injection, where it restores protective processes to diseased joints and enables the regeneration of affected tissues. It works by blocking a compound that supports the nerve cells involved in transmitting pain signals to the brain.
This doesn't say it just blocks the pain, it says it directly affects the nerve cells involved in transmitting pain. Those nerve cells could also be responsible for other unpleasant things, like generally complaining and always being inflamed and inhibiting proper healing.
j45|1 year ago
deamanto|1 year ago
[1] - https://en.wikipedia.org/wiki/Bedinvetmab
zukzuk|1 year ago
One theory is that the immune system eventually starts attacking the monoclonal antibody med itself, another is that as in humans, the OA progression might accelerate under the drug.
bittercynic|1 year ago
My dog's been on it since last October, and it's made a big difference for him. Sorry to hear that it didn't help yours.
I've been wondering how long it would be before something similar was available for humans.
dl9999|1 year ago
stef25|1 year ago